Medicare's $50 obesity drug program gains traction at drugstores

Medicare's new "Bridge" program, designed to make obesity drugs more accessible, is showing early signs of success, according to major pharmacy chains CVS and Walgreens. The program, which commenced on July 1, allows certain Medicare beneficiaries to obtain weight-loss medications for a subsidized cost of $50 per month.

Both CVS and Walgreens have reported substantial participation in the initiative. Each company has already dispensed 100,000 prescriptions under the Bridge program, indicating a strong demand among eligible Medicare recipients for these treatments.

The program's aim is to address the growing concern over obesity and its associated health risks by improving access to pharmacological interventions. By capping the monthly cost, Medicare seeks to reduce financial barriers that might otherwise prevent beneficiaries from starting or continuing treatment.

While the article does not detail the specific eligibility criteria for the program or the types of obesity drugs covered, the reported prescription numbers suggest that the $50 price point is a significant incentive for those who qualify. Further details on the program's long-term impact and reach are expected as it continues to operate.